|
A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis) Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis) conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis) Clinical research trials and A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis) healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis). A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis) Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis) clinical trial. Test subjects oftentimes recieve the best healthcare possible for their A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis) condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis)  A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis)
A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis)
For Condition: Cystic Fibrosis
Status: Recruiting
Sponsor(s): National Center for Research Resources (NCRR) , Cystic Fibrosis Foundation Therapeutics
Synopsis: We are testing a new combination of medicines, to determine if they could be used to treat cystic fibrosis (CF). Subjects with CF who have two copies of the most common mutation (change) found in patients with CF called DF508. CF is caused by a lack of chloride movement in the nose, sinuses, lungs, intestines, pancreas and sweat glands. We are conducting this study to determine the safety of using a combination of two medicines, Phenylbutyrate and Genistein, to improve the ability of the cells lining the nose to regulate movement of salt (chloride) and water in people with CF. Phenylbutyrate has been extensively used to treat patients with rare metabolic diseases (which are very different from CF), Phenylbutyrate is an investigational drug for the purpose of this study. Genistein is a naturally occurring substance that is found in food products such as soy and tofu, but is also an investigational drug for this study. Both drugs may be able to restore normal chloride movements in body organs and glands. We will be studying salt and water in the nose movement by a technique called nasal transepithelial potential difference (NPD).
Details: Subjects will be randomized to receive either the Phenylbutyrate or placebo tablets for 1 week, with a 2 out of 3 chance of receiving Phenylbutyrate at a standard adult dose, with visits on study days 1, 4, and 7. The study will last an additional 2 weeks to determine whether the effects of the Phenylbutyrate or Placebo persist for any length of time, with visits on study days 14 and 21. Every participant will receive the Genistein during the NPD on days 1 and 7. The dose of Genistein used will not be escalated and will be the same for every participant. Safety evaluations at each visit will include a history, and physical exam and mental status exam, blood and urine tests, and lung function tests. The main physiologic outcome of the trial will be the assessment of salt and water transport NPD. In this way, we will assess whether genistein enhances the effect of phenylbutyrate to improve chloride transport in the nose by topical application of genistein to the nasal mucosa during the NPD procedure on study days 1 and 7.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: a) All ethnic groups b) Females and males c) 18 years of age or older d) Able to communicate with pertinent staff, able to understand and willing to comply with the requirements of the trial, and able and willing to give informed consent. e) Willing to practice a reliable and study-accepted method of contraception during the study Acceptable methods are abstinence, barrier methods, or oral contraceptives. (This is predominantly directed at female subjects, as males with CF are typically sterile due to obstructive azospermia. We will encourage males to use barrier methods for the duration of the study on the small chance that fertility exists). f) Diagnosis of cystic fibrosis consisting of both: - sweat sodium or chloride > 60 mEq/L by the pilocarpine iontophoresis method and cystic fibrosis genotype homozygous for DF508-CFTR - clinical manifestations of cystic fibrosis h) Oxyhemoglobin saturation ? 92% while breathing room air
Total Enrollment:
Location and Contact Information:
Children's Hospital of Philadelphia *Recruiting*
Philadelphia, Pennsylvania, 19101
United States
Recruiting Ronald Rubenstein 215-590-1281
Additional Information:
Study ID Numbers: NCRR-M01RR00240-1765;
Study Start Date:
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00016744
Other Cystic Fibrosis Studies:
1. Efficacy and Safety of 24 Weeks of Oral Treatment with BIIL 284 BS in Adult and Pediatric Patients
2. Diabetes Therapy to Improve BMI and Lung Function in CF
3. Phase II Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin for Cystic Fibrosis
4. Interferon gamma-1b by inhalation for the treatment of patients with cystic fibrosis
5. Tissue Collection from People with Cystic Fibrosis
Related Studies:
Other Cystic Fibrosis Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials
A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis)
|
|
|
|
|
|
|
|
